INTERLEUKIN-17INHIBITION WITH SECUKINUMAB IMPROVES SUDOMOTOR DYSFUNCTION IN PSORIATIC ARTHRITIS

Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2018, Vol 10, Issue 3

Abstract

Psoriatic arthritis (PsA) is a relapsing inflammatory disease, most commonly a seronegative oligoarthritis found in patients with psoriasis, characterized by the absence of rheumatoid factor in serum, with differentiating features of distal joint involvement and in extreme cases of arthritis mutilans (which is a destructive form of PsA). Cardiovascular autonomic and peripheral sympathetic neuropathy occurs in PsA. However, there is no specific treatment recommendation for autonomic neuropathy (AN) in psoriatic diseases. Secukinumab, a recently approved therapeutic advancement for psoriasis and psoriatic arthritis, is an immunoglobulin G (IgG) 1k fully monoclonal antibody that selectively inhibits the effector function of interleukin (IL)-17A. Its effect on sudomotor dysfunction in PsA has not yet been reported. This is the first reported observation of improvement in peripheral sympathetic autonomic neuropathy with secukinumab in PsA. We report a case of a 52-year-old male with PsA on methotrexate 15 mg/week with severe disease activity treated with the addition of subcutaneous secukinumab 150 mg once a week for 5 w followed by once a month dose. We found significant improvement in sudomotor dysfunction after 4 and 8 w of treatment.

Authors and Affiliations

Ashit Syngle, Inderjeet Verma, Sudeep Kaur, Tanya Syngle

Keywords

Related Articles

AN INVESTIGATION INTO ELECTROMAGNETIC BASED IMPEDANCE TOMOGRAPHY USING REALISTIC HUMAN HEAD MODEL

The objective of this research is to investigate the feasibility of Electromagnetic based Impedance Tomography (EMIT) for brain stroke detection, localization and classification. Electromagnetic based Impedance Tomograph...

SUPER GENERICS / IMPROVED THERAPEUTIC ENTITIES: AN APPROACH TO FULFIL UNMET MEDICAL NEEDS AND EXTENDING MARKET EXCLUSIVITY OF GENERIC MEDICINES

The generic market is more competitive & the pharmaceutical market players are looking for developing newer versions of generics by adding value to the product and getting the extension in market exclusivity for the...

A SURVEY OF DRUG-RELATED-PROBLEMS AMONG PATIENTS TREATED FOR ALLERGY SYMPTOMS IN COMMUNITY PHARMACIES AT NEGERI SEMBILAN, MALAYSIA

Objectives: Patients treated for allergy symptoms are at risk of acquiring drug-related problems (DRPs), as they require various types and forms of medications. Inappropriate therapeutic management of allergy symptoms co...

SAMPLE-A RAW DATA FOR FUTURE INFORMATION OF LIFE

Gene amplification requires a biological sample which is collected prior to the demands. The sample for such analysis plays a vital role as they serve as a resource for the core material-Deoxyribonucleic acid. A sample f...

INCREASING THE SOLUBILITY OF DIPYRIDAMOLE USING POLYETHYLENE GLYCOLS

Objective: The objective of the present study is a determination of the limiting solubility of dipyridamole in water and optimal ratios of polyethylene glycol:dipyridamole at which formation of solid dispersion is observ...

Download PDF file
  • EP ID EP567566
  • DOI 10.22159/ijpps.2018v10i3.22660
  • Views 73
  • Downloads 0

How To Cite

Ashit Syngle, Inderjeet Verma, Sudeep Kaur, Tanya Syngle (2018). INTERLEUKIN-17INHIBITION WITH SECUKINUMAB IMPROVES SUDOMOTOR DYSFUNCTION IN PSORIATIC ARTHRITIS. International Journal of Pharmacy and Pharmaceutical Sciences, 10(3), 167-169. https://www.europub.co.uk/articles/-A-567566